Rabbani Shaik, Lumeena Shaik, Sreenivasa Prasanna P
Prevention and control is indeed the medicinal, scientific knowledge concerning this same error checking, evaluation, better understanding as well as preventative measures like negative impacts, significantly longer concept but also near term adverse effects like medications. The purpose of prevention and control is really to lengthen the security going to monitor as well as to identify every adrs a certain presumably received underrecognized through transformation all through medical study. Prevention and control have indeed been great at playing a major role in reasonable drug utilization related while also providing information about adverse reactions occurring throughout the patient. Indian pharmaceutical technology is indeed the third biggest on the planet when it comes to quantity but also seventeen highest when it comes to valuation. The nation has also become a centre such as medical research and drug development, as well as the advances in innovation, contaminant moieties, active ingredients, and medicines becoming revealed as well as designed and made on a wide scale. National pharmaceutical technology involves a worldwide and normalized quality management system such as improved providing a safe assessment. This helps to explain the need for that pharmaceutical technology, the initial principles connected between prevention and control, as well as the present state of both medication management inside the nation.
{"title":"Pharmacovigilance: Need for Indian Pharma Industry","authors":"Rabbani Shaik, Lumeena Shaik, Sreenivasa Prasanna P","doi":"10.26452/fjphs.v3i3.490","DOIUrl":"https://doi.org/10.26452/fjphs.v3i3.490","url":null,"abstract":"Prevention and control is indeed the medicinal, scientific knowledge concerning this same error checking, evaluation, better understanding as well as preventative measures like negative impacts, significantly longer concept but also near term adverse effects like medications. The purpose of prevention and control is really to lengthen the security going to monitor as well as to identify every adrs a certain presumably received underrecognized through transformation all through medical study. Prevention and control have indeed been great at playing a major role in reasonable drug utilization related while also providing information about adverse reactions occurring throughout the patient. Indian pharmaceutical technology is indeed the third biggest on the planet when it comes to quantity but also seventeen highest when it comes to valuation. The nation has also become a centre such as medical research and drug development, as well as the advances in innovation, contaminant moieties, active ingredients, and medicines becoming revealed as well as designed and made on a wide scale. National pharmaceutical technology involves a worldwide and normalized quality management system such as improved providing a safe assessment. This helps to explain the need for that pharmaceutical technology, the initial principles connected between prevention and control, as well as the present state of both medication management inside the nation.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87158204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alagusundaram M, P. Keshri, M. Tyagi, N. Jain, G. Venkateshwarlu, D. Gupta
In the current study, wet granulation with various concentrations and combinations of excipients like magnesium stearate as a lubricant, talc as glident, DCP as diluent, and PVP K 30 as a binder successfully produced floating tablets of rosiglitazone maleate. These excipients included HPMC K15M, xanthan gum, sodium bicarbonate, and tartaric acid as gas-generating agents. We investigated every pre-compressional parameter, including angle of repose, bulk density, and Carr's index. Drug content, hardness, friability, weight fluctuation, in-vitro dissolving experiments, floating qualities, and stability investigations were performed on the compressed tablets. According to in-vitro experiments, the release time increases up to 6, 8, and 10 hours, respectively, as the content of HPMC K15M in formulations F1, F2, and F3 is raised. For formulations F4, F5, and F6, adding xanthan gum raised the release to 7, 9, and 11 hours, respectively. In formulations F7, F8, and F9, the release was found to be increased up to 8, 10, and 12 hours, respectively, with the addition of HPMC K 15 M and Xanthan gum. F9 was discovered to be the finest formulation since it could maintain release for up to 12 hours. All formulations displayed "n" value for Peppa's plot in the range of 0.45 to 0.89, demonstrating anomalous transport (non-Fickian diffusion) as the method of drug release. The improved formulation (F9) was demonstrated to be stable and intact without any contact over the course of 90 days.
{"title":"Formulation Development and Characterization of Floating Drug Delivery System of Rosiglitazone Maleate","authors":"Alagusundaram M, P. Keshri, M. Tyagi, N. Jain, G. Venkateshwarlu, D. Gupta","doi":"10.26452/fjphs.v3i3.488","DOIUrl":"https://doi.org/10.26452/fjphs.v3i3.488","url":null,"abstract":"In the current study, wet granulation with various concentrations and combinations of excipients like magnesium stearate as a lubricant, talc as glident, DCP as diluent, and PVP K 30 as a binder successfully produced floating tablets of rosiglitazone maleate. These excipients included HPMC K15M, xanthan gum, sodium bicarbonate, and tartaric acid as gas-generating agents. We investigated every pre-compressional parameter, including angle of repose, bulk density, and Carr's index. Drug content, hardness, friability, weight fluctuation, in-vitro dissolving experiments, floating qualities, and stability investigations were performed on the compressed tablets. According to in-vitro experiments, the release time increases up to 6, 8, and 10 hours, respectively, as the content of HPMC K15M in formulations F1, F2, and F3 is raised. For formulations F4, F5, and F6, adding xanthan gum raised the release to 7, 9, and 11 hours, respectively. In formulations F7, F8, and F9, the release was found to be increased up to 8, 10, and 12 hours, respectively, with the addition of HPMC K 15 M and Xanthan gum. F9 was discovered to be the finest formulation since it could maintain release for up to 12 hours. All formulations displayed \"n\" value for Peppa's plot in the range of 0.45 to 0.89, demonstrating anomalous transport (non-Fickian diffusion) as the method of drug release. The improved formulation (F9) was demonstrated to be stable and intact without any contact over the course of 90 days.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"os-20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87202066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lack of drug standardization is the main obstacle preventing Siddha pharmaceuticals from being recognized more frequently in poorer nations. The current study also standardized a Siddha herbal-mineral creation of KMNC that indicated cervical cancer by investigating its physio-chemical. Fourier transforms infrared radiation properties. It was performed to produce evidence-based statistics about this new formulation and to give researchers helpful information. The drug particle size was determined by SEM examination. XRF analysis was used to determine the medication's component percentage. On-to-be nanometers indicate that the experimental drug may have effective drug delivery. The physicochemical characteristics also instrumental investigations of KMNC are discussed in this work as part of standardization by AYUSH Guidelines. This Indian medical system describes KMNC as a white powder containing herbs, metal, also mineral ingredients. The physio-chemical assessment's findings show that KMNC has a specific gravity of 0.927, a pH assessment of 7.8, also percentage of losses after 105 ? C 0.3±0.05568 %, and a total ash rate of 1.2%.
{"title":"Kaalamega Narayana Chendhooram (KMNC): Standardization, Characterization, and Instrumental Analysis of a Potential Anti- Oral, Anti-Lung, and Anti-Prostate Cancer of Herbal Mineral Formulation (A Siddha Medicine for Oral, Lung, and Prostate Cancer)","authors":"S. C, B. S, K. D, A. R","doi":"10.26452/fjphs.v3i3.487","DOIUrl":"https://doi.org/10.26452/fjphs.v3i3.487","url":null,"abstract":"Lack of drug standardization is the main obstacle preventing Siddha pharmaceuticals from being recognized more frequently in poorer nations. The current study also standardized a Siddha herbal-mineral creation of KMNC that indicated cervical cancer by investigating its physio-chemical. Fourier transforms infrared radiation properties. It was performed to produce evidence-based statistics about this new formulation and to give researchers helpful information. The drug particle size was determined by SEM examination. XRF analysis was used to determine the medication's component percentage. On-to-be nanometers indicate that the experimental drug may have effective drug delivery. The physicochemical characteristics also instrumental investigations of KMNC are discussed in this work as part of standardization by AYUSH Guidelines. This Indian medical system describes KMNC as a white powder containing herbs, metal, also mineral ingredients. The physio-chemical assessment's findings show that KMNC has a specific gravity of 0.927, a pH assessment of 7.8, also percentage of losses after 105 ? C 0.3±0.05568 %, and a total ash rate of 1.2%.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83715635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The aim of the present research work was to formulate Transdermal patches of Clotrimazole and to enhance effectiveness and to avoid side effects of the drug. Transdermal patch of clotrimazole was prepared with EC and HPMC in different ratios in order to improve the drug diffusion. Clotrimazole has formulated Transdermal patches were prepared by solvent evaporation technique. Drug and polymers has been characterized by FT-IR. The FTIR spectra of formulation shows that no interaction between drug and excipient. The evaluation of Transdermal patches of Clotrimazole were performed mainly for their Physical parameters such as Weight variation, Thickness, Folding endurance test And also for their Drug content and In-vitro Drug diffusion studies. The patch prepared by solvent evaporation technique passes the prepared patch were found to be non irritant, weight variation was found in the range of 39±5.81 to 48±2.90mg, thickness in the range of 0.08±0.09 to 0.04±0.08 mm, Folding endurance of patches was found to be in the range of 98 ±0.57 to 128±0.59, The tensile strength of the patches was ranging from 1.95±1.2to 3.98±1.9, The percentage elongation ranges from 10.6 to 18.6, drug content uniformity was in between 78.25 to 89.76 %. The in-vitro drug diffusion profiles of the formulations in pH 7.4 show differences depending on their composition. A Tran’s dermal patches of all the preparations were observed by the diffusion test. It was also observed that F6 showed highest drug release.
{"title":"Formulation and Evaluation of Transdermal Patches of Clotrimazole","authors":"Yelamanda Jagadeesh","doi":"10.26452/fjphs.v3i3.482","DOIUrl":"https://doi.org/10.26452/fjphs.v3i3.482","url":null,"abstract":"The aim of the present research work was to formulate Transdermal patches of Clotrimazole and to enhance effectiveness and to avoid side effects of the drug. Transdermal patch of clotrimazole was prepared with EC and HPMC in different ratios in order to improve the drug diffusion. Clotrimazole has formulated Transdermal patches were prepared by solvent evaporation technique. Drug and polymers has been characterized by FT-IR. The FTIR spectra of formulation shows that no interaction between drug and excipient. The evaluation of Transdermal patches of Clotrimazole were performed mainly for their Physical parameters such as Weight variation, Thickness, Folding endurance test And also for their Drug content and In-vitro Drug diffusion studies. The patch prepared by solvent evaporation technique passes the prepared patch were found to be non irritant, weight variation was found in the range of 39±5.81 to 48±2.90mg, thickness in the range of 0.08±0.09 to 0.04±0.08 mm, Folding endurance of patches was found to be in the range of 98 ±0.57 to 128±0.59, The tensile strength of the patches was ranging from 1.95±1.2to 3.98±1.9, The percentage elongation ranges from 10.6 to 18.6, drug content uniformity was in between 78.25 to 89.76 %. The in-vitro drug diffusion profiles of the formulations in pH 7.4 show differences depending on their composition. A Tran’s dermal patches of all the preparations were observed by the diffusion test. It was also observed that F6 showed highest drug release.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87110684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Test","authors":"Anandh A","doi":"10.26452/fjphs.v3i2.466","DOIUrl":"https://doi.org/10.26452/fjphs.v3i2.466","url":null,"abstract":"c","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135795743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Test","authors":"Anandh A","doi":"10.26452/fjphs.v3i2.459","DOIUrl":"https://doi.org/10.26452/fjphs.v3i2.459","url":null,"abstract":"Checking.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"253 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136355351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Test","authors":"Anandh A","doi":"10.26452/fjphs.v3i2.456","DOIUrl":"https://doi.org/10.26452/fjphs.v3i2.456","url":null,"abstract":"Checking.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135915914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Test","authors":"Anandh A","doi":"10.26452/fjphs.v3i2.452","DOIUrl":"https://doi.org/10.26452/fjphs.v3i2.452","url":null,"abstract":"checking.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136261258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Test","authors":"Anandh A","doi":"10.26452/fjphs.v3i2.451","DOIUrl":"https://doi.org/10.26452/fjphs.v3i2.451","url":null,"abstract":"check","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136370223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Test","authors":"Anandh A","doi":"10.26452/fjphs.v3i2.448","DOIUrl":"https://doi.org/10.26452/fjphs.v3i2.448","url":null,"abstract":"Check.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"48 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135099832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：